Overview Assessment of V0018 2.5 mg Effect on Craving Status: Completed Trial end date: 2015-05-01 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the reduction of craving and its time course after administration of V0018 2.5 mg compared to placebo in healthy highly dependant smokers. Phase: Phase 2 Details Lead Sponsor: Pierre Fabre MedicamentTreatments: Nicotine